Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor α in normal and tumor-bearing mice

Jody A. Krosnick, Joe K. McIntosh, James J. Mulé, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Tumor-bearing mice have a greater sensitivity to the acute lethal effects of the administration of high-dose recombinant human tumor necrosis factor α (rhTNF-α) compared to normal, non-tumor-bearing mice. We studied whether or not the presence of tumor per se was responsible for the enhanced rhTNF-α toxicity. Tumor-bearing mice underwent tumor excision or sham operation before the systemic administration of rhTNFα at staged times (0.5-24 h) following surgery. There was little survival difference between sham-operated tumor-bearing mice and tumor-bearing mice undergoing tumor excision (at 24 h, treatment with 12 μg rhTNF-α, survival:sham-operated tumor bearers = 0/12, excised tumor-bearers = 0/12;P2 <0.01 compared to non-tumor-bearers). Mice without tumors receiving sham operation, had minimal toxicity (10 of 12 mice surviving). The injection of 3 ml Ringer's lactate i.p. before i.v. rhTNF-α therapy increased survival in tumor-bearing animals; following pretreatment with Ringer's lactate 30/42 mice survived 12 μg rhTNF-α compared to 6/42 surviving a similar rhTNF-α dose without hydration (P2 <0.001). Since the production of oxygen free-radical metabolites has been postulated to play a role in the acute toxicity of rhTNF-α, bismuth subnitrate was used to induce the enzyme metallothionein to act as a natural scavenger for these metabolites. Daily oral bismuth subnitrate treatments improved survival of mice with MCA-106 or MCA-102 sarcoma and of mice without tumors, with higher rhTNF-α doses (12-20 μg), without reducing the therapeutic effect of rhTNF-α against the weakly immunogenic MCA-106 sarcoma. These studies suggest methods for reducing the toxicity of rhTNF-α administration in clinical trials.

Original languageEnglish (US)
Pages (from-to)133-138
Number of pages6
JournalCancer Immunology Immunotherapy
Volume30
Issue number3
DOIs
StatePublished - May 1 1989

    Fingerprint

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this